| Acquired by | Celgene |
| Price | $925M |
| Date | 1/12 |
| Terms | Cash |
| Website | avilatx.com |
| Category | BioTech |
| Phone | 781-891-0086 |
| info@avilatx.com | |
| Employees |
| TOTAL | $4M |
| FUNDING TOTAL | $4M |
| Venture Round, 1/12 Clovis Oncology | $4M |
Avila Therapeutics is a clinical-stage biotechnology company focused on the design and development of targeted covalent drugs to achieve best-in class outcomes. This approach, called “protein silencingâ€, cannot be achieved through traditional chemistry techniques. The company’s product pipeline has been built using its proprietary Avilomicsâ„¢ platform and is currently focused on cancer, viral infection and autoimmune disease. Avila’s most advanced product candidate, AVL-292, a potential treatment for cancer and autoimmune diseases, is currently in Phase 1 clinical testing. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners.
